Aspol Trans S.c. Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: Aspol Trans S.c. Pharmaceutical Import Records from India — 3 Products, $30.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aspol Trans S.c. — Pharmaceutical Importer Profile (2026) | 3 Products, $30.5K Trade | TransData Nexus

Aspol Trans S.c.

Pharmaceutical Importer · Poland · Ayurvedic & Herbal Products Focus · $30.5K Total Trade · DGFT Verified

Aspol Trans S.c. is a pharmaceutical importer based in Poland with a total trade value of $30.5K across 3 products in 1 therapeutic categories. Based on 42 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Aspol Trans S.c. sources from 5 verified Indian suppliers, with Combitic Global Caplet Private Limited accounting for 60.1% of imports.

Aspol Trans S.c. — Import Portfolio & Supplier Network

Aspol Trans S.c. import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Aspol Trans S.c.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Combitic Global Caplet Private Limited	$783.7K	488	60.1%
Jangir Exports	$278.5K	162	21.3%
Anchal Enterprises	$93.5K

What Formulations Does Aspol Trans S.c. Import?

Formulation	Value	Ships
Triphala	$41.5K	7
Neem tablet	$41.5K	4
Rumalaya gel 30 GM	$37.8K	3
Shatavari	$36.8K	7
Ashwaganda	$35.6K	5
Zandu trishun TAB 6 s x	$28.4K	1
Ashwagangha TAB 60	$19.4K	1
Rumalaya forte	$17.7K	4
Trishun tablet	$17.3K	1
Brahmi TAB 60	$16.4K	3
Tiger balm red	$16.0K	4
Mukta vati	$15.9K	1
Brahmi tablet	$15.9K	4
Koflet lozenges 160+40	$15.8K	2
Ashwagandha TAB	$15.7K	1

Aspol Trans S.c. imports 883 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Kwatha	Ayurvedic & Herbal Products	$24.6K	27	4.6%	3
2	Ghrita	Ayurvedic & Herbal Products	$3.4K	13	0.7%	10
3	Gutika	Ayurvedic & Herbal Products	$2.5K	2	2.0%	14

Aspol Trans S.c. imports 3 pharmaceutical products across 1 categories into Poland totaling $30.5K.

Aspol Trans S.c. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Aspol Trans S.c. is a pharmaceutical importer based in Poland, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a range of pharmaceutical products to meet the needs of the Polish market. Headquartered in Gdynia, Poland, Aspol Trans S.c. plays a significant role in the distribution of imported pharmaceutical products within the country. While specific details about its parent company are not publicly available, Aspol Trans S.c. is recognized for its focus on importing Ayurvedic and herbal products, indicating a niche specialization within the pharmaceutical import sector.

2Distribution Network

Specific information regarding Aspol Trans S.c.'s warehouse locations and logistics capabilities is not publicly disclosed. However, given its role as a pharmaceutical importer, it is likely that the company collaborates with established logistics providers to ensure efficient distribution within Poland. The company's geographic coverage primarily focuses on the Polish market, with potential for expansion into neighboring European countries, depending on demand and regulatory approvals.

3Industry Role

Aspol Trans S.c. functions as a pharmaceutical importer, sourcing finished pharmaceutical formulations from India to supply the Polish market. Its role is pivotal in introducing Ayurvedic and herbal products into Poland, catering to a segment of the population seeking alternative medicinal options. By importing these products, Aspol Trans S.c. contributes to the diversification of available pharmaceutical treatments in Poland, meeting the demand for natural and traditional remedies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Aspol Trans S.c.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Aspol Trans S.c. demonstrates a high level of sourcing concentration, with its top five products accounting for 100% of its imports from India. This indicates a strategic focus on a select range of Ayurvedic and herbal formulations. The company's primary suppliers include COMBITIC GLOBAL CAPLET PRIVATE LIMITED, JANGIR EXPORTS, ANCHAL ENTERPRISES, VINAYAKA EXPORTS, and YUVANSH INTERNATIONAL, with COMBITIC GLOBAL CAPLET PRIVATE LIMITED accounting for 60.1% of the total import value. This concentration suggests a strong, possibly exclusive, relationship with these suppliers, which could be advantageous in terms of pricing and supply chain stability. However, such dependency also poses risks; any disruption with these suppliers could significantly impact Aspol Trans S.c.'s ability to meet market demand.

2Supply Chain Resilience

The resilience of Aspol Trans S.c.'s supply chain is closely tied to its reliance on a limited number of Indian suppliers. While this focus may streamline operations and strengthen supplier relationships, it also exposes the company to potential risks such as supply disruptions, geopolitical issues, or regulatory changes in India. The company's import data indicates a diverse range of 883 unique formulations, which may help mitigate some risks by not relying on a single product line. However, the heavy reliance on a few suppliers for these formulations suggests that any issues with these suppliers could have a substantial impact on Aspol Trans S.c.'s operations.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Chief Pharmaceutical Inspectorate (Główny Inspektorat Farmaceutyczny, GIF) is the primary regulatory authority overseeing the import and distribution of medicinal products. The Pharmaceutical Law of 6 September 2001, along with subsequent amendments, governs the importation, marketing, and distribution of pharmaceuticals in Poland. For Indian generics to be marketed in Poland, they must undergo a marketing authorization process, which includes demonstrating bioequivalence to the reference product and compliance with Good Manufacturing Practice (GMP) standards. The marketing authorization is granted by the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL), ensuring that imported generics meet the necessary safety, efficacy, and quality standards.

2Import Licensing & GMP

Importers of medicinal products in Poland must obtain an import license from the Chief Pharmaceutical Inspectorate. This license is required for activities such as storage, quality control, and distribution of medicinal products within Poland. The GMP certificate recognition is crucial; Indian manufacturers must hold a valid GMP certificate recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S, to ensure that their products meet the required quality standards. Additionally, importers must possess wholesale distribution authorization, which is granted by the Chief Pharmaceutical Inspectorate upon verification of compliance with all regulatory requirements.

Aspol Trans S.c. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Aspol Trans S.c.'s focus on importing Ayurvedic and herbal products aligns with a growing consumer interest in natural and alternative medicines in Poland. The market demand for such products is driven by consumers seeking holistic health solutions and a preference for traditional remedies. By specializing in this niche, Aspol Trans S.c. caters to a specific segment of the population, differentiating itself from competitors and establishing a strong presence in the market for Ayurvedic and herbal pharmaceuticals.

2Sourcing Profile

Aspol Trans S.c. employs a sourcing strategy that emphasizes importing generic drugs from India, focusing on Ayurvedic and herbal formulations. This approach allows the company to offer cost-effective alternatives to branded products while meeting the demand for natural medicinal options in Poland. India's established reputation in producing high-quality generic pharmaceuticals makes it a strategic partner for Aspol Trans S.c., enabling the company to provide a diverse range of products to the Polish market.

3Market Positioning

Based on its product mix, Aspol Trans S.c. serves a segment of the Polish market that includes retail pharmacies, health food stores, and consumers seeking alternative medicinal products. By focusing on Ayurvedic and herbal products, the company positions itself as a specialized importer catering to the growing demand for natural and traditional remedies, distinguishing itself from mainstream pharmaceutical distributors.

Seller's Guide — How to Become a Supplier to Aspol Trans S.c.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Polish market through Aspol Trans S.c., especially if they can offer unique Ayurvedic and herbal formulations that complement the existing product range. Gaps in Aspol Trans S.c.'s current sourcing may include specific therapeutic areas or product forms not currently covered. Indian exporters can explore these opportunities by understanding the unmet needs in the Polish market and aligning their offerings accordingly.

2Requirements & Qualifications

Indian exporters aiming to supply Aspol Trans S.c. and the Polish market must ensure that their products comply with EU GMP standards and hold a valid GMP certificate recognized by the European Union. Additionally, they must obtain marketing authorization from the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) in Poland, demonstrating bioequivalence to the reference product and compliance with all regulatory requirements.

3How to Approach

Frequently Asked Questions — Aspol Trans S.c.

What products does Aspol Trans S.c. import from India?

Aspol Trans S.c. imports 3 pharmaceutical products across 1 categories. Top imports: Kwatha ($24.6K), Ghrita ($3.4K), Gutika ($2.5K).

Who supplies pharmaceuticals to Aspol Trans S.c. from India?

Aspol Trans S.c. sources from 5 verified Indian suppliers. The primary supplier is Combitic Global Caplet Private Limited (60.1% of imports, $783.7K).

What is Aspol Trans S.c.'s total pharmaceutical import value?

Aspol Trans S.c.'s total pharmaceutical import value from India is $30.5K, based on 42 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Aspol Trans S.c. focus on?

Aspol Trans S.c. imports across 1 categories. The largest: Ayurvedic & Herbal Products (100.0%).

Get Full Aspol Trans S.c. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.